Enrolment in the ongoing trials, LITESPARK-005 (NCT04195750), LITESPARK-011 (NCT04586231), and LITESPARK-012 (NCT04736706), needs to be completed to assess whether VHL loss could be a predictive factor of response to Belzutifan in ccRCC since Belzutifan is administered regardless of the VHL status in the aforementioned trials. This evidence concerns the gene VHL and nonpapillary renal cell carcinoma.